Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

MRK US​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings
Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

MRK US​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings

Merck & Co., Inc.(MRK US)

$146.95-0.230.16%Ext:$147.25+0.300.21%(Market Closed · 00:55:35 UTC)
Ask AI
Doc SearchProfileEntity StructureFinancialsChartingShort InterestEmployees

Overview

ProfileEntity Structure

Documents

SEC Filings

Merck & Co., Inc.(MRK US)

$146.95-0.230.16%Ext:$147.25+0.300.21%(Market Closed · 00:55:35 UTC)
Ask AI
Doc SearchProfileEntity StructureFinancialsChartingShort InterestEmployees

Overview

ProfileEntity Structure

Documents

SEC Filings

Financials & Metrics

FinancialsChartingShort InterestEmployees

Financials & Metrics

FinancialsChartingShort InterestEmployees

Merck & Co., Inc. — Company Profile

Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.

Sector
Health Care
Industry
Pharmaceuticals
Exchange
UN
CEO
Robert Davis
Headquarters
Rahway, NJ, US
IPO Date
Jan 13, 1978
Employees
74,000
Website
www.merck.com

Key Metrics

Price
$144.30
Market Cap
$356.40B
Revenue (TTM)
$16.29B
Net Income (TTM)
$-4240000000.00
EPS (TTM)
-1.72
P/E (TTM)
39.89
P/B (TTM)
7.77
Dividend Yield
2.83%
ROE (TTM)
-9.24%
ROA (TTM)
-3.29%
Operating Margin
-11.57%
Beta
0.11

Dividends

Last Dividend
$0.85
Last Yield
0.03%

Summary

Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.

Website
www.merck.com
Location
Rahway, NJ, US
Phone908 740 4000
Employees74,000
CEORobert Davis
Sector
Health Care
Industry
Pharmaceuticals
IPO DateJan 13, 1978

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.
How it makes money
A short diagram of the business model.

Latest Documents

SEC Filings(3K)

Expand
  • 10-QQ3ended 30 Sept 20264 Nov
  • Form 4DIAZ PAUL J3 Nov
  • Form 3DIAZ PAUL J3 Nov
  • Form 144Williams David Michael2 Nov
  • 8-KResults of Operations and Financial Condition29 Oct
  • Form 3/AMaraldo David R.22 Oct
  • 25-NSENotification of removal from listing15 Oct
  • 8-KDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers13 Oct
  • Form 4Seidman Christine E1 Oct
  • Form 4Karsanbhai Surendralal Lanca1 Oct
  • Form 4Coe Mary Ellen1 Oct
  • Form 3Gupta Gaurav K1 Sep
  • Form 4Guindo Chirfi13 Aug
  • Form 144Guindo Chirfi13 Aug
  • Form 4Zachary Jennifer13 Aug
  • Form 144DeLuca Richard R.12 Aug
  • Form 144Zachary Jennifer12 Aug
  • Form 4DeLuca Richard R.12 Aug
  • Form 144DeLuca Richard R.11 Aug
  • Form 144DeLuca Richard R.10 Aug

News

  • 3 Pharmaceutical Stocks That Offer Safety and Growth12 Nov
  • What Merck KGaA (MRK) Said on Its Q3 Earnings Call12 Nov
  • Merck to Participate in the Jefferies Global Healthcare Conference in London12 Nov
  • Want a Dividend Check Every Month? This Dividend ETF Paid You 12 Times in the Past Year11 Nov
  • Americans Fill Prescriptions Every Month, and $90,000 Across These 3 Drugmakers Pays $3,650 a Year11 Nov
  • EXCLUSIVE: Lilly, Gilead Face Near-Term Drug Pricing Risks As Washington Turns Up Heat11 Nov
  • FDA Approves PIMJETMI® (pimicotinib) for Patients with Tenosynovial Giant Cell Tumor10 Nov
  • Merck Announces Positive Results from Phase 2b Trial of Efinopegdutide in Adults with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Stage 2-3 Fibrosis9 Nov
  • Merck Announces Positive Results from Phase 2b Trial of Efinopegdutide in Adults with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Stage 2-3 Fibrosis9 Nov
  • INVA or MRK: Which Is the Better Value Stock Right Now?9 Nov
  • MRK's 2027 Outlook Challenging, Long-Term Prospects Promising9 Nov
  • Two 70-Year-Olds Will Start the Same $12,272 Keytruda Qlex Cancer Injections. One With Medigap Plan G Will Owe $0 in Coinsurance After the Part B Deductible, While the Other Will Owe 20% With No Annual Cap8 Nov
  • Merck & Co., Inc. $MRK Stock Purchased by Asset One Wealth Management LLC8 Nov
  • Merck Stock Shows Sustained Strength: Time to Buy, Sell or Hold?6 Nov
  • Merck & Co., Inc. $MRK Stock Acquired by Compass Financial Management LLC6 Nov
  • MRK's Keytruda & Gardasil Sales Rise in Q3: Can the Momentum Last?5 Nov
  • Merck & Co., Inc. $MRK Shares Sold by Boston Trust Walden Corp5 Nov
  • November Dogs Of The Dow: No Buys, Yet 5 Are Worth Watching4 Nov
  • AIA Group Ltd Sells 55,326 Shares of Merck & Co., Inc. $MRK4 Nov
  • 6,400 Merck & Co., Inc. $MRK Shares Purchased by Aware Super Pty Ltd as trustee of Aware Super4 Nov

Mentions in Filings

  • … al cell carcinoma following PD-1 or PD-L1 inhibitor therapy. An application for this combination therapy is currently pending in Japan. In April 2026, a pre-specified interim analysis of a Phase III trial conducted by <strong>Merck & Co.</strong> for advanced renal cell carcinoma (first-line) showed that the triple combination therapy of pembrolizumab and verzutifan failed to meet the primary endpoints of overall survival and progression-free survival compared t …
    Eisai Co., Ltd.Merck & Co., Inc.·Interim Report - Semi-Annual Report (2026.04.01-2027.03.31)·12 Nov·11 Nov
  • … tition will also arise from non-cell-based therapies pursued by small-cap biotechnology and large-cap pharmaceutical companies including Amgen Inc., AstraZeneca plc, Bristol Myers Squibb Company, Incyte Corporation, <strong>Merck & Co., Inc.</strong>, and F. Hoffmann-La Roche AG. Many of our competitors, either alone or with their collaboration partners, have significantly greater financial resources and expertise in research and development, preclinical testing, …
    Celularity IncMerck & Co., Inc.·ARS - Annual report to security holders·FY25·10 Nov
  • … ersity Medical School; Lead PI for numerous guideline-changing regulatory approvals Peter Blume-Jensen, M.D., Ph.D. Chief Executive Officer, President and Co-Founder, Acrivon Therapeutics; Formerly Executive at Serono, <strong>Merck & Co.</strong>, Daiichi Sankyo, Metamark Genetics; Inventor of the AP3 Platform Erick Gamelin, M.D., Ph.D. Chief Development Officer, Acrivon Therapeutics; Formerly CEO for national cancer center; Executive at Pfizer, AMGEN, Dynavax, …
    Acrivon Therapeutics, Inc.Merck & Co., Inc.·EX-99.1 - 8-K - Regulation FD Disclosure·Q4 26·10 Nov
  • … l positions at Pfizer Inc., including Head, Medical Affairs, Safety and Regulatory Affairs for Pfizer’s human health business. Dr. Morrison also previously held several positions at Merck Research Laboratories, a division of <strong>Merck & Co., Inc.</strong>, including Vice President, Clinical Sciences, Oncology. He was a member of the executive committee of the Clinical Trials Transformation Initiative sponsored by the FDA and is on 182 --- TABLE OF CONTENTS
    Werewolf Therapeutics, Inc.Merck & Co., Inc.·S-4/A - Registration statement (business combination, amendment)·Q4 26·10 Nov
  • … and Regeneron has received FDA approval for aflibercept and aflibercept HD. AbbVie is currently collaborating with RegenexBio Inc. (“RegenexBio”) to develop ABBV-RGX-314 as a potential gene therapy treatment for nAMD. <strong>Merck & Co.</strong> is developing MK-3000, a tri-specific antibody, and MK-8748, a bispecific antibody, for DME and nAMD. In December 2025, Lilly completed the acquisition of Adverum Biotechnologies, Inc. (“Adverum”), including its portfol …
    Kalaris Therapeutics, Inc.Merck & Co., Inc.·10-Q - Quarterly report Q3·Q3 26·10 Nov
  • … ome effective on January 1, 2027. On January 27, 2026, CMS published the list of 15 drugs selected for the third cycle of negotiations. These negotiated prices will become effective on January 1, 2028. On June 6, 2023, <strong>Merck & Co.</strong> filed a lawsuit against HHS and CMS asserting that, among other things, the IRA’s Drug Price Negotiation Program for Medicare constitutes an uncompensated taking in violation of the Fifth Amendment of the U.S. Constitut …
    Hemab Therapeutics Holdings, Inc.Merck & Co., Inc.·10-Q - Quarterly report Q3·Q3 26·10 Nov

Key Stats

Trading

Px/Chg 1D$144.30 / +0.34%
Avg Volume10.25M
Beta0.11
Mkt Cap356.40B
FD Mkt Cap364.40B

Float

Shrs Out/Float2.47B / 2.47B
Short Float0.01%
Days to Cover2.30
Stock Repurchased$874.00M

Current Valuation

EV400.24B
EV/EBITDA20.18
EV/Sales6.10
P/B7.77
P/S5.43
FCF Yield0.82%
ROE-9.24%
ROA-3.29%
Current Ratio1.30

Dividend

Cash$0.85
Yield2.83%
Yield (TTM)2.83%

Estimates

P/E39.89
Est P/E0.00
Est EPS-1.47
Est PEG0.00

Valuation

Metric5Yr AvgMay '23May '24May '25May '26Oct '26
PRICE-BASED RATIOS
Price / Earnings191.7120.47916.1412.3293.67-84.06
Price / Sales10.555.015.563.2917.0021.88
Price / Book Value6.596.468.904.555.287.77
Price / Free Cash Flow68.4720.2136.5711.65152.17121.76
ENTERPRISE VALUE METRICS
Enterprise Value326,026.1316,538.8363,873.2235,901.3313,579.1400,238.0
Enterprise Value / Sales11.775.346.053.6819.2124.58
Enterprise Value / EBITDA-14.2914.8552.689.1849.80-197.94
Enterprise Value / EBIT23.5618.19119.8911.1281.85-113.25

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue7.5%48,704.059,283.060,115.064,168.064,926.0
Gross Income7.4%35,078.041,872.043,989.048,975.046,731.0
EBITDA12.1%17,899.021,315.06,907.025,706.028,262.0
EBIT11.2%14,685.017,406.03,035.021,207.022,424.0
Net Income8.8%13,049.014,519.0365.017,117.018,254.0
EPS (Diluted)9.1%5.145.710.146.747.28
BALANCE SHEET
Cash & ST Inv15.8%8,096.013,192.07,093.013,689.014,565.0
Total Assets6.7%105,694.0109,160.0106,675.0117,106.0136,866.0
Total Liabilities5.7%67,437.063,102.069,040.070,734.084,204.0
Total Shareholder Equity8.3%38,184.045,991.037,581.046,313.052,606.0
CASH FLOW
Net Operating Cash Flow3.9%14,109.019,095.013,006.021,468.016,472.0
Cap Ex-1.9%-4,448.0-4,388.0-3,863.0-3,372.0-4,112.0
Free Cash Flow6.4%9,661.014,707.09,143.018,096.012,360.0

Enterprise Value Bridge

Millions USD12 Nov '26
Price (As of 12 Nov '26)147.91
Basic Shares2,469.82
Market Cap365,311.1
Diluted Shares2,478.00
Fully Diluted Shares Outstanding2,478.00
Fully Diluted Market Cap366,521.0
+Consolidated Debt53,777.0
−In-the-Money Convertible Debt—
+Capital Leases-
+Operating Leases—
−Cash & Equivalents-9,550.0
−Short-term Investments-100.0
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest53.0
+Pension Liabilities—
Enterprise Value409,591.1

Segment data

Revenue

by Products and services

  • Pharmaceutical Segment89%
  • Animal Health Segment10%
  • Other Segments1%

Revenue

by Geography

  • United States56%
  • Emea22%
  • Latin America5%
  • Asia Pacific5%
  • International4%

Related companies

Eli Lilly and Company

LLY US

Johnson & Johnson

JNJ US

AbbVie Inc.

ABBV US

Novartis Ag

NVS US

Astrazeneca Plc

AZN US

Abbott Laboratories

ABT US

Novo Nordisk A/S

NVO US

Pfizer Inc

PFE US

Vertex Pharmaceuticals Inc / Ma

VRTX US

Bristol Myers Squibb Company

BMY US

Csl Ltd

CSLLY US

Sanofi

SNY US

Merck & Co., Inc. — Company Profile

Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.

Sector
Health Care
Industry
Pharmaceuticals
Exchange
UN
CEO
Robert Davis
Headquarters
Rahway, NJ, US
IPO Date
Jan 13, 1978
Employees
74,000
Website
www.merck.com

Key Metrics

Price
$144.30
Market Cap
$356.40B
Revenue (TTM)
$16.29B
Net Income (TTM)
$-4240000000.00
EPS (TTM)
-1.72
P/E (TTM)
39.89
P/B (TTM)
7.77
Dividend Yield
2.83%
ROE (TTM)
-9.24%
ROA (TTM)
-3.29%
Operating Margin
-11.57%
Beta
0.11

Dividends

Last Dividend
$0.85
Last Yield
0.03%

Summary

Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.

Website
www.merck.com
Location
Rahway, NJ, US
Phone908 740 4000
Employees74,000
CEORobert Davis
Sector
Health Care
Industry
Pharmaceuticals
IPO DateJan 13, 1978

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.
How it makes money
A short diagram of the business model.

Latest Documents

SEC Filings(3K)

Expand
  • 10-QQ3ended 30 Sept 20264 Nov
  • Form 4DIAZ PAUL J3 Nov
  • Form 3DIAZ PAUL J3 Nov
  • Form 144Williams David Michael2 Nov
  • 8-KResults of Operations and Financial Condition29 Oct
  • Form 3/AMaraldo David R.22 Oct
  • 25-NSENotification of removal from listing15 Oct
  • 8-KDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers13 Oct
  • Form 4Seidman Christine E1 Oct
  • Form 4Karsanbhai Surendralal Lanca1 Oct
  • Form 4Coe Mary Ellen1 Oct
  • Form 3Gupta Gaurav K1 Sep
  • Form 4Guindo Chirfi13 Aug
  • Form 144Guindo Chirfi13 Aug
  • Form 4Zachary Jennifer13 Aug
  • Form 144DeLuca Richard R.12 Aug
  • Form 144Zachary Jennifer12 Aug
  • Form 4DeLuca Richard R.12 Aug
  • Form 144DeLuca Richard R.11 Aug
  • Form 144DeLuca Richard R.10 Aug

News

  • 3 Pharmaceutical Stocks That Offer Safety and Growth12 Nov
  • What Merck KGaA (MRK) Said on Its Q3 Earnings Call12 Nov
  • Merck to Participate in the Jefferies Global Healthcare Conference in London12 Nov
  • Want a Dividend Check Every Month? This Dividend ETF Paid You 12 Times in the Past Year11 Nov
  • Americans Fill Prescriptions Every Month, and $90,000 Across These 3 Drugmakers Pays $3,650 a Year11 Nov
  • EXCLUSIVE: Lilly, Gilead Face Near-Term Drug Pricing Risks As Washington Turns Up Heat11 Nov
  • FDA Approves PIMJETMI® (pimicotinib) for Patients with Tenosynovial Giant Cell Tumor10 Nov
  • Merck Announces Positive Results from Phase 2b Trial of Efinopegdutide in Adults with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Stage 2-3 Fibrosis9 Nov
  • Merck Announces Positive Results from Phase 2b Trial of Efinopegdutide in Adults with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Stage 2-3 Fibrosis9 Nov
  • INVA or MRK: Which Is the Better Value Stock Right Now?9 Nov
  • MRK's 2027 Outlook Challenging, Long-Term Prospects Promising9 Nov
  • Two 70-Year-Olds Will Start the Same $12,272 Keytruda Qlex Cancer Injections. One With Medigap Plan G Will Owe $0 in Coinsurance After the Part B Deductible, While the Other Will Owe 20% With No Annual Cap8 Nov
  • Merck & Co., Inc. $MRK Stock Purchased by Asset One Wealth Management LLC8 Nov
  • Merck Stock Shows Sustained Strength: Time to Buy, Sell or Hold?6 Nov
  • Merck & Co., Inc. $MRK Stock Acquired by Compass Financial Management LLC6 Nov
  • MRK's Keytruda & Gardasil Sales Rise in Q3: Can the Momentum Last?5 Nov
  • Merck & Co., Inc. $MRK Shares Sold by Boston Trust Walden Corp5 Nov
  • November Dogs Of The Dow: No Buys, Yet 5 Are Worth Watching4 Nov
  • AIA Group Ltd Sells 55,326 Shares of Merck & Co., Inc. $MRK4 Nov
  • 6,400 Merck & Co., Inc. $MRK Shares Purchased by Aware Super Pty Ltd as trustee of Aware Super4 Nov

Mentions in Filings

  • … al cell carcinoma following PD-1 or PD-L1 inhibitor therapy. An application for this combination therapy is currently pending in Japan. In April 2026, a pre-specified interim analysis of a Phase III trial conducted by <strong>Merck & Co.</strong> for advanced renal cell carcinoma (first-line) showed that the triple combination therapy of pembrolizumab and verzutifan failed to meet the primary endpoints of overall survival and progression-free survival compared t …
    Eisai Co., Ltd.Merck & Co., Inc.·Interim Report - Semi-Annual Report (2026.04.01-2027.03.31)·12 Nov·11 Nov
  • … tition will also arise from non-cell-based therapies pursued by small-cap biotechnology and large-cap pharmaceutical companies including Amgen Inc., AstraZeneca plc, Bristol Myers Squibb Company, Incyte Corporation, <strong>Merck & Co., Inc.</strong>, and F. Hoffmann-La Roche AG. Many of our competitors, either alone or with their collaboration partners, have significantly greater financial resources and expertise in research and development, preclinical testing, …
    Celularity IncMerck & Co., Inc.·ARS - Annual report to security holders·FY25·10 Nov
  • … ersity Medical School; Lead PI for numerous guideline-changing regulatory approvals Peter Blume-Jensen, M.D., Ph.D. Chief Executive Officer, President and Co-Founder, Acrivon Therapeutics; Formerly Executive at Serono, <strong>Merck & Co.</strong>, Daiichi Sankyo, Metamark Genetics; Inventor of the AP3 Platform Erick Gamelin, M.D., Ph.D. Chief Development Officer, Acrivon Therapeutics; Formerly CEO for national cancer center; Executive at Pfizer, AMGEN, Dynavax, …
    Acrivon Therapeutics, Inc.Merck & Co., Inc.·EX-99.1 - 8-K - Regulation FD Disclosure·Q4 26·10 Nov
  • … l positions at Pfizer Inc., including Head, Medical Affairs, Safety and Regulatory Affairs for Pfizer’s human health business. Dr. Morrison also previously held several positions at Merck Research Laboratories, a division of <strong>Merck & Co., Inc.</strong>, including Vice President, Clinical Sciences, Oncology. He was a member of the executive committee of the Clinical Trials Transformation Initiative sponsored by the FDA and is on 182 --- TABLE OF CONTENTS
    Werewolf Therapeutics, Inc.Merck & Co., Inc.·S-4/A - Registration statement (business combination, amendment)·Q4 26·10 Nov
  • … and Regeneron has received FDA approval for aflibercept and aflibercept HD. AbbVie is currently collaborating with RegenexBio Inc. (“RegenexBio”) to develop ABBV-RGX-314 as a potential gene therapy treatment for nAMD. <strong>Merck & Co.</strong> is developing MK-3000, a tri-specific antibody, and MK-8748, a bispecific antibody, for DME and nAMD. In December 2025, Lilly completed the acquisition of Adverum Biotechnologies, Inc. (“Adverum”), including its portfol …
    Kalaris Therapeutics, Inc.Merck & Co., Inc.·10-Q - Quarterly report Q3·Q3 26·10 Nov
  • … ome effective on January 1, 2027. On January 27, 2026, CMS published the list of 15 drugs selected for the third cycle of negotiations. These negotiated prices will become effective on January 1, 2028. On June 6, 2023, <strong>Merck & Co.</strong> filed a lawsuit against HHS and CMS asserting that, among other things, the IRA’s Drug Price Negotiation Program for Medicare constitutes an uncompensated taking in violation of the Fifth Amendment of the U.S. Constitut …
    Hemab Therapeutics Holdings, Inc.Merck & Co., Inc.·10-Q - Quarterly report Q3·Q3 26·10 Nov

Key Stats

Trading

Px/Chg 1D$144.30 / +0.34%
Avg Volume10.25M
Beta0.11
Mkt Cap356.40B
FD Mkt Cap364.40B

Float

Shrs Out/Float2.47B / 2.47B
Short Float0.01%
Days to Cover2.30
Stock Repurchased$874.00M

Current Valuation

EV400.24B
EV/EBITDA20.18
EV/Sales6.10
P/B7.77
P/S5.43
FCF Yield0.82%
ROE-9.24%
ROA-3.29%
Current Ratio1.30

Dividend

Cash$0.85
Yield2.83%
Yield (TTM)2.83%

Estimates

P/E39.89
Est P/E0.00
Est EPS-1.47
Est PEG0.00

Valuation

Metric5Yr AvgMay '23May '24May '25May '26Oct '26
PRICE-BASED RATIOS
Price / Earnings191.7120.47916.1412.3293.67-84.06
Price / Sales10.555.015.563.2917.0021.88
Price / Book Value6.596.468.904.555.287.77
Price / Free Cash Flow68.4720.2136.5711.65152.17121.76
ENTERPRISE VALUE METRICS
Enterprise Value326,026.1316,538.8363,873.2235,901.3313,579.1400,238.0
Enterprise Value / Sales11.775.346.053.6819.2124.58
Enterprise Value / EBITDA-14.2914.8552.689.1849.80-197.94
Enterprise Value / EBIT23.5618.19119.8911.1281.85-113.25

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue7.5%48,704.059,283.060,115.064,168.064,926.0
Gross Income7.4%35,078.041,872.043,989.048,975.046,731.0
EBITDA12.1%17,899.021,315.06,907.025,706.028,262.0
EBIT11.2%14,685.017,406.03,035.021,207.022,424.0
Net Income8.8%13,049.014,519.0365.017,117.018,254.0
EPS (Diluted)9.1%5.145.710.146.747.28
BALANCE SHEET
Cash & ST Inv15.8%8,096.013,192.07,093.013,689.014,565.0
Total Assets6.7%105,694.0109,160.0106,675.0117,106.0136,866.0
Total Liabilities5.7%67,437.063,102.069,040.070,734.084,204.0
Total Shareholder Equity8.3%38,184.045,991.037,581.046,313.052,606.0
CASH FLOW
Net Operating Cash Flow3.9%14,109.019,095.013,006.021,468.016,472.0
Cap Ex-1.9%-4,448.0-4,388.0-3,863.0-3,372.0-4,112.0
Free Cash Flow6.4%9,661.014,707.09,143.018,096.012,360.0

Enterprise Value Bridge

Millions USD12 Nov '26
Price (As of 12 Nov '26)147.91
Basic Shares2,469.82
Market Cap365,311.1
Diluted Shares2,478.00
Fully Diluted Shares Outstanding2,478.00
Fully Diluted Market Cap366,521.0
+Consolidated Debt53,777.0
−In-the-Money Convertible Debt—
+Capital Leases-
+Operating Leases—
−Cash & Equivalents-9,550.0
−Short-term Investments-100.0
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest53.0
+Pension Liabilities—
Enterprise Value409,591.1

Segment data

Revenue

by Products and services

  • Pharmaceutical Segment89%
  • Animal Health Segment10%
  • Other Segments1%

Revenue

by Geography

  • United States56%
  • Emea22%
  • Latin America5%
  • Asia Pacific5%
  • International4%

Related companies

Eli Lilly and Company

LLY US

Johnson & Johnson

JNJ US

AbbVie Inc.

ABBV US

Novartis Ag

NVS US

Astrazeneca Plc

AZN US

Abbott Laboratories

ABT US

Novo Nordisk A/S

NVO US

Pfizer Inc

PFE US

Vertex Pharmaceuticals Inc / Ma

VRTX US

Bristol Myers Squibb Company

BMY US

Csl Ltd

CSLLY US

Sanofi

SNY US